Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety and Efficacy Study in Healthy Adults of Intranasal Norwalk Virus-like Particle Vaccine in Experimental Human Norwalk Virus Infection

Trial Profile

Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety and Efficacy Study in Healthy Adults of Intranasal Norwalk Virus-like Particle Vaccine in Experimental Human Norwalk Virus Infection

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Norovirus vaccine (Primary) ; Chitosan; Monophosphoryl lipid A
  • Indications Gastroenteritis; Norovirus infections
  • Focus Therapeutic Use
  • Sponsors LigoCyte Pharmaceuticals
  • Most Recent Events

    • 30 Dec 2011 Status changed from active, no longer recruiting to completed, results have been published in full in the NEJM.
    • 08 Dec 2011 Primary endpoint 'Vaccine-protective-efficacy' has been met (3065398).
    • 25 Oct 2010 Results were presented at the at the Infectious Diseases Society of America (IDSA), according to a LigoCyte Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top